ANN ARBOR, Mich., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol
– Esperion to Receive $300 Million in Upfront and Near-term Milestones – – Up to $900 Million in Total Milestones – – Substantial Tiered Royalties – – Esperion Partnering with a European CV Sales Organization Exceeding 1000 and One of the Most Successful European-based
ANN ARBOR, Michigan , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein
